Palisade Bio, INC

Palisade Bio appointed Jordan Zwick to its Board of Directors and received stockholder approval to increase authorized common stock to 450 million shares.

Palisade Bio announced first quarter 2026 financial results, highlighting progress in its PALI-2108 clinical program for inflammatory bowel disease and a strong cash position.

Palisade Bio has entered into a master services agreement with Iterative Health and raised $3 million through a private placement of common stock to support its PALI-2108 Phase 2 study.

Palisade Bio stockholders approved an increase in authorized common stock and the issuance of shares underlying warrants at a special meeting.

Palisade Bio, Inc. announced the termination of its Phantom Unit Plan, resulting in the forfeiture of unvested awards for key executives.

Palisade Bio, Inc. stockholders approved a reverse stock split, elected three directors, and ratified Baker Tilly US, LLP as their independent auditor at the annual meeting.

Palisade Bio, Inc. filed its Q1 2026 10-Q report, detailing a net loss of $9.6 million and significant increases in R&D and G&A expenses, while highlighting positive clinical trial results for its lead candidate, PALI-2108.

Palisade Bio reported positive Phase 1 clinical trial results for PALI-2108 in IBD, secured $138 million in a public offering, and addressed its going concern status, despite ongoing net losses and internal control weaknesses.

Palisade Bio announced a reduced net loss in Q2 2025, positive Phase 1 clinical trial results for PALI-2108, and a recent $3.9 million warrant exercise, but faces ongoing going concern doubts and Nasdaq compliance monitoring.

Palisade Bio announces its Q1 2025 financial results, showcasing a decrease in net loss and providing updates on the clinical development of its lead product candidate, PALI-2108.

Palisade Bio's Q3 2024 report highlights progress in their PALI-2108 clinical program, including the commencement of a Phase 1 trial, while also noting ongoing financial challenges.

Palisade Bio's second quarter 2024 report highlights ongoing development of PALI-2108, recent financings, and a focus on cost management.

Palisade Bio reported positive Phase 1 clinical trial results for its lead IBD drug candidate PALI-2108, secured $127.6 million in financing, and outlined plans for Phase 2 studies in 2026.

Palisade Bio's 10-K filing reveals ongoing net losses and substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidate PALI-2108.

Palisade Bio pivots to pre-clinical development of PALI-2108 for inflammatory bowel disease after terminating its LB1148 program.

Palisade Bio, Inc. Director Robert Baltera Jr. reported the acquisition of 45,000 shares of common stock through multiple transactions.

Robert Baltera Jr., a Director at Palisade Bio, Inc., has acquired a total of 50,000 shares of common stock through multiple transactions.

Palisade Bio's Chief Medical Officer, Mitchell Lawrence Jones, reported transactions involving the settlement of Restricted Stock Units and the subsequent sale of shares to cover tax obligations.

John David Finley, CEO and Director of Palisade Bio, Inc., reported transactions involving the acquisition and sale of company stock, including shares to cover tax withholding obligations.

Robert Baltera Jr., a Director at Palisade Bio, Inc., has acquired 30,000 shares of common stock through open market purchases.

Palisade Bio, Inc. Director Robert Baltera Jr. acquired 336,904 shares of common stock.

Palisade Bio, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026, to vote on key proposals including director elections and equity plan approvals.

Palisade Bio, Inc. filed a supplement to its proxy statement, correcting the number of outstanding common shares for its upcoming Special Meeting due to recent warrant exercises.

Palisade Bio, Inc. calls a Special Meeting for December 3, 2025, to vote on issuing shares for warrants and increasing authorized common stock.

Palisade Bio, Inc. is urgently soliciting stockholder votes for its upcoming Annual Meeting on October 17, 2025, emphasizing the need for active participation.

Palisade Bio, Inc. has filed a definitive proxy statement with the SEC, signaling an upcoming shareholder meeting.

Palisade Bio, Inc. will hold its 2025 Annual Meeting to vote on director elections, auditor ratification, and a reverse stock split to regain Nasdaq compliance.

Palisade Bio, Inc. filed an S-1MEF registration statement to offer up to $24.5 million in common stock and warrants to fund its operations.

Palisade Bio, a clinical-stage biopharmaceutical company, is offering up to 147 million shares and pre-funded warrants to raise approximately $92.4 million for advancing its lead IBD candidate, PALI-2108, despite ongoing Nasdaq listing concerns and going concern doubt.

Palisade Bio, a clinical-stage biopharmaceutical company, announced a public offering of common stock and pre-funded warrants to raise approximately $8.9 million, following positive Phase 1 clinical trial results for its lead IBD candidate, PALI-2108.

Clinical-stage biopharmaceutical company Palisade Bio, Inc. is offering up to 2,857,142 Class A Units and Class B Units to raise capital for its Phase 1 clinical trial and other development activities.

Clinical-stage biopharmaceutical company Palisade Bio, Inc. is offering 2,427,184 shares of common stock and pre-funded warrants to purchase up to 2,427,184 shares, alongside representative warrants for up to 145,631 shares, to raise capital for clinical trials and operations.

Palisade Bio has filed an amendment to its registration statement for a public offering of common stock and pre-funded warrants, aiming to raise up to $5.75 million to support its clinical development programs.

Soleus Capital Master Fund and affiliated entities have reported a 5.4% beneficial ownership stake in Palisade Bio, Inc. common stock.

RA Capital Management and its principals report a 9.9% beneficial ownership stake in Palisade Bio, Inc. as of March 31, 2026.

Point72 Asset Management, L.P. and Steven A. Cohen have filed a Schedule 13G reporting a 0.2% beneficial ownership stake in Palisade Bio, Inc.

Commodore Capital LP and its principals have reported a 7.2% beneficial ownership stake in Palisade Bio, Inc. through a combination of common stock and pre-funded warrants.

Perceptive Advisors LLC and Joseph Edelman have reported a 7.9% beneficial ownership stake in Palisade Bio, Inc. through the Perceptive Life Sciences Master Fund.

Ameriprise Financial, Inc. and its subsidiary Columbia Management Investment Advisers, LLC have reported beneficial ownership of 5.3% of Palisade Bio, Inc.'s common stock as of March 31, 2026.